167 related articles for article (PubMed ID: 38250680)
1. Evaluating staging laparoscopy indications for pancreatic cancer based on resectability classification and treatment strategies for patients with positive peritoneal washing cytology.
Igarashi T; Fukasawa M; Watanabe T; Kimura N; Itoh A; Tanaka H; Shibuya K; Yoshioka I; Hirabayashi K; Fujii T
Ann Gastroenterol Surg; 2024 Jan; 8(1):124-132. PubMed ID: 38250680
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of staging laparoscopy for resectable pancreatic cancer on imaging and the therapeutic effect of systemic chemotherapy for positive peritoneal cytology.
Fukasawa M; Watanabe T; Tanaka H; Itoh A; Kimura N; Shibuya K; Yoshioka I; Murotani K; Hirabayashi K; Fujii T
J Hepatobiliary Pancreat Sci; 2023 Nov; 30(11):1261-1272. PubMed ID: 37750024
[TBL] [Abstract][Full Text] [Related]
3. Clinical Benefits of Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Institution, Retrospective Analysis.
Mataki Y; Kurahara H; Idichi T; Tanoue K; Hozaka Y; Kawasaki Y; Iino S; Maemura K; Shinchi H; Ohtsuka T
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33801465
[TBL] [Abstract][Full Text] [Related]
4. Predictive impacts of peritoneal washing cytology for surgical resection-intended pancreatic cancer cases: Establishment of planned staging laparoscopy criteria.
Tanaka N; Takami H; Hayashi M; Inokawa Y; Kurimoto K; Hattori N; Kanda M; Tanaka C; Nakayama G; Kodera Y
J Hepatobiliary Pancreat Sci; 2023 Nov; 30(11):1273-1281. PubMed ID: 37799038
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Staging Laparoscopy in Patients With Pancreatic Cancer: A Single Center Prospective Cohort Study.
Shindo Y; Tokumitsu Y; Matsui H; Nakajima M; Kimura Y; Iida M; Suzuki N; Takeda S; Ioka T; Nagano H
In Vivo; 2023; 37(6):2704-2709. PubMed ID: 37905607
[TBL] [Abstract][Full Text] [Related]
6. 18F-fluorodeoxyglucose positron emission tomography to indicate conversion surgery in patients with initially unresectable locally advanced pancreatic cancer.
Okano K; Suto H; Oshima M; Ando Y; Nagao M; Kamada H; Kobara H; Masaki T; Okuyama H; Okita Y; Tsuji A; Suzuki Y
Jpn J Clin Oncol; 2018 May; 48(5):434-441. PubMed ID: 29590448
[TBL] [Abstract][Full Text] [Related]
7. A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma.
Satoi S; Yanagimoto H; Yamamoto T; Toyokawa H; Hirooka S; Yamaki S; Opendro SS; Inoue K; Michiura T; Ryota H; Matsui Y; Kon M
World J Surg Oncol; 2016 Jan; 14(1):14. PubMed ID: 26791083
[TBL] [Abstract][Full Text] [Related]
8. Conversion surgery with gemcitabine plus nab-paclitaxel for locally advanced unresectable pancreatic cancer: A case report.
Okura R; Takano S; Yokota T; Yoshitomi H; Kagawa S; Furukawa K; Takayashiki T; Kuboki S; Suzuki D; Sakai N; Nojima H; Mishima T; Miyazaki M; Ohtsuka M
Mol Clin Oncol; 2018 Oct; 9(4):389-393. PubMed ID: 30214727
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression.
Kobayashi M; Mizuno S; Murata Y; Kishiwada M; Usui M; Sakurai H; Tabata M; Ii N; Yamakado K; Inoue H; Shiraishi T; Yamada T; Isaji S
Pancreas; 2014 Apr; 43(3):350-60. PubMed ID: 24622063
[TBL] [Abstract][Full Text] [Related]
10. Survival equivalence in patients treated for borderline resectable and unresectable locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis.
Lindemann J; du Toit L; Kotze U; Bernon M; Krige J; Jonas E
HPB (Oxford); 2021 Feb; 23(2):173-186. PubMed ID: 33268268
[TBL] [Abstract][Full Text] [Related]
11. Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma.
Yanagimoto H; Satoi S; Yamamoto T; Yamaki S; Hirooka S; Kotsuka M; Ryota H; Ishida M; Matsui Y; Sekimoto M
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32486418
[TBL] [Abstract][Full Text] [Related]
12. Prognosis of Pancreatic Cancer Based on Resectability: A Single Center Experience.
Einama T; Takihata Y; Aosasa S; Konno F; Kobayashi K; Yonamine N; Fujinuma I; Tsunenari T; Nakazawa A; Shinto E; Ueno H; Kishi Y
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831444
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of a locally advanced unresectable pancreatic cancer patient with interstitial pneumonitis by conversion surgery following gemcitabine plus nab-paclitaxel chemotherapy: A case report.
Yokota T; Takano S; Yoshitomi H; Kagawa S; Furukawa K; Takayashiki T; Kuboki S; Suzuki D; Sakai N; Nojima H; Mishima T; Nakadai E; Ohtsuka M
Mol Clin Oncol; 2019 Apr; 10(4):419-424. PubMed ID: 30931110
[TBL] [Abstract][Full Text] [Related]
14. Reappraisal of the validity of surgery for patients with pancreatic cancer aged 80 years or older stratified by resectability status.
Kondo N; Uemura K; Nakagawa N; Okada K; Seo S; Takahashi S; Murakami Y
J Hepatobiliary Pancreat Sci; 2020 Feb; 27(2):64-74. PubMed ID: 31602815
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma Stratified by the Resectability Status.
Sakoda T; Uemura K; Kondo N; Sumiyoshi T; Okada K; Seo S; Otsuka H; Murakami Y; Takahashi S
J Gastrointest Surg; 2021 Nov; 25(11):2871-2880. PubMed ID: 33768425
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of multimodal treatment including chemoradiotherapy, conversion surgery and postoperative chemotherapy for borderline resectable and unresectable locally advanced pancreatic cancer without disease progression after gemcitabine plus nab-paclitaxel.
Umezawa R; Mizuma M; Nakagawa K; Yamamoto T; Takahashi N; Suzuki Y; Kishida K; Omata S; Unno M; Jingu K
Pancreatology; 2023 Sep; 23(6):650-656. PubMed ID: 37453848
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of intraoperative peritoneal washing cytology for patients with potentially resectable pancreatic ductal adenocarcinoma.
Hoshimoto S; Hishinuma S; Shirakawa H; Tomikawa M; Ozawa I; Hoshi N; Hoshi S; Hirabayashi K; Ogata Y
Pancreatology; 2017; 17(1):109-114. PubMed ID: 27840175
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Peritoneal Lavage Cytology in Potentially Resectable Pancreatic Cancer Stratified by Cytologic Status.
Ishida H; Ogura T; Takahashi A; Kitamura K; Miyamoto R; Matsudaira S; Tanabe M; Kanda H; Kawashima Y
Cancer Diagn Progn; 2023; 3(3):338-346. PubMed ID: 37168974
[TBL] [Abstract][Full Text] [Related]
19. Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma.
Quan K; Sutera P; Xu K; Bernard ME; Burton SA; Wegner RE; Zeh H; Bahary N; Stoller R; Heron DE
Pract Radiat Oncol; 2018; 8(2):95-106. PubMed ID: 29291966
[TBL] [Abstract][Full Text] [Related]
20. Triple modal treatment comprising with proton beam radiation, hyperthermia, and gemcitabine/nab-paclitaxel for locally advanced pancreatic cancer: a phase I/II study protocol (TT-LAP trial).
Shimomura O; Endo M; Makishima H; Yamada T; Hashimoto S; Numajiri H; Miyazaki Y; Doi M; Furuya K; Takahashi K; Moriwaki T; Hasegawa N; Yamamoto Y; Niisato Y; Kobayashi M; Mizumoto M; Nakai K; Saito T; Hoshiai S; Saida T; Mathis BJ; Mori K; Nakajima T; Tsuchiya K; Sakurai H; Oda T
BMC Cancer; 2023 Jul; 23(1):624. PubMed ID: 37403011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
